Featured Story | By Kyle LaHucik Bristol Myers Squibb and Nektar Therapeutics said a phase 3 trial of the biotech's bempegaldesleukin combined with the Big Pharma's checkpoint inhibitor Opdivo in patients with untreated unresectable or metastatic melanoma failed. The drug was part of BMS' commitment of up to $3.6 billion to Nektar in 2018, which was the largest licensing deal in biotech history at the time. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Sanofi’s oral selective estrogen receptor degrader amcenestrant has flunked a pivotal trial. The failure of amcenestrant as a second-line or later treatment of ER+/HER2- advanced or metastatic breast cancer leaves Sanofi looking to studies in earlier-stage patients to rescue the potential blockbuster. read more By Annalee Armstrong Roche will not be beaten when it comes to pharma R&D. The company lands at No. 1 on our Pharma R&D budget list once again, but who else made it? read more By Nick Paul Taylor BridgeBio Pharma has posted an upbeat update on its limb-girdle muscular dystrophy type 2i program. With a phase 2 trial linking BBP-418 to positive biomarker changes, BridgeBio is preparing to talk to regulators about paths to market for the treatment of muscle wasting in the arms and legs. read more By Max Bayer Ascendis Pharma checked off its top boxes in a phase 3 hypoparathyroidism trial, improving calcium levels in nearly 80% of patients treated and lessening disease severity. The PaTHway trial's primary endpoint was a composite measure of serum calcium levels and independence from conventional therapy with no increase in the study drug, TransCon PTH, within the four weeks prior to the week 26 visit. read more By Kyle LaHucik Nutcracker Therapeutics snagged $167 million to bankroll development of messenger RNA therapies for cancer. The California biotech will also build out its manufacturing platform across discovery, clinical and commercialization stages. read more By Conor Hale Some of the largest drugmakers tackling Alzheimer’s disease and its related dementias are banding together to ensure their pursuits make the best use of the truly massive amounts of digital data that can be gathered from patients as the companies look to track their progress. read more By Angus Liu Lynparza is solidifying its lead in the PARP inhibitor class. The AstraZeneca and Merck drug has nabbed an FDA approval as a post-surgery adjuvant treatment for a specific type of breast cancer and posted an updated survival win. read more By Kevin Dunleavy A week after Italian vials manufacturer Stevanato announced a $95 million deal with the U.S. government to expand operations at its facility under construction in Fishers, Indiana, the company says it has acquired a plant in Zhangjiagang, China, which it will expand to 32,000 square feet. read more By Anastassia Gliadkovskaya Many households did not have enough assets to pay the typical deductibles and most can’t afford to meet high deductibles. read more By Fraiser Kansteiner Sandoz is beefing up in respiratory medicine even as parent company Novartis weighs the generics outfit's future. The company on Monday said it acquired British medical and drug delivery device developer Coalesce Product Development. Meanwhile, Novartis' strategic review of Sandoz, launched last October, rolls on. read more By Andrea Park The recall encompasses more than 277,000 devices distributed in the U.S. between early 2015 and this year, according to the FDA. read more By Angus Liu Scientists at Yale University have found a way to enhance the cancer-killing power of CAR-T cells by reprogramming an amino acid metabolism pathway. The discovery could guide the development of cell therapies with improved tumor control, the researchers said, and potentially enable them to treat solid tumors. read more By Max Bayer The long-debated Alzheimer's biomarker amyloid beta may play an active role in the spread of melanoma cells in the brain, according to new research from NYU Langone. The researchers found that the peptides were in higher numbers in the brain than elsewhere in the body and that they shielded the cancer cells from the body's immune response. read more Resources Sponsored by: Medidata, a Dassault Systèmes company The landscape of clinical trials has been permanently changed. Today's trials require sponsors to modernize their use of technology and data to adapt. This eBook provides an overview of how sponsors can empower trials with real-time performance data to improve study integrity, reduce risks, optimize patient safety, and increase trial success rates. Sponsored by: Thermo Fisher Scientific Learn how to navigate the top manufacturing challenges and achieve a seamless transition from discovery to clinical manufacturing across the CAR T-cell therapy workflow. Sponsored by: Oracle Health Sciences Learn about ways to break down regulatory roadblocks and get closer to 100% clarity on regulatory positions to advance decentralized clinical trials in research. Sponsored by: Oracle Health Sciences How to overcome top challenges faced in decentralized trials. Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Fierce BD&L Summit for Life Sciences March 15-16, 2022 | San Francisco, CA Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Pharma PR & Communications Summit West June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce MedTech Summit August 8-9, 2022 | Minneapolis, MN Promotional Review Committee Compliance and Best Practices Summit West (PRC West) September 2022 | San Diego, CA Medical Affairs Strategic Summit (MASS West) September 2022 | San Diego, CA Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce Pharma Marketing Awards October 19, 2022 | Philadelphia, PA Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 
